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Ex vivo biochemical analysis of rectal biopsies of a carrier of the mild 2789+5 G-A CFTR frameshift splice site mutation revealed mutant
truncated CFTR of expected size and an imbalance of more core-glycosylated and less mature full-length CFTR. This first immunoblot
analysis of a non-F508del CFTR mutant protein derived from human tissue demonstrates that splice site mutations should not only be
investigated at the mRNA, but also at the protein level to properly interpret the associations between genotype, molecular pathology and
disease.
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More than 1500 mutations and sequence variations have
been identified in the Cystic Fibrosis Transmenbrane
Conductance Regulator (CFTR) gene (http://genet.sickkids.
on.ca/cftr/), the majority of which causes cystic fibrosis (CF)
[1]. The mutant phenotype has been studied for numerous
mutations in patients’specimens at the mRNA transcript
level [1]. Mutant CFTR protein, however, was mainly
investigated in heterologous model systems. The few
immunocytochemical or biochemical studies on human
specimens focussed on the major mutation F508del [2,3],
mainly because of the lack of sufficiently sensitive and
specific tools and protocols. According to our knowledge,
this is the first report of the biochemical phenotype of a non-
F508del mutant CFTR protein in native human epithelial
tissue.⁎ Corresponding author. Klinische Forschergruppe, Abt. für Pädiatrische
Pneumologie und Neonatologie, OE 6710, Medizinische Hochschule
Hannover, D-30625 Hannover, Germany. Tel.: +49 511 5322920; fax: +49
511 5326723.
E-mail address: tuemmler.burkhard@mh-hannover.de (B. Tümmler).
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doi:10.1016/j.jcf.2007.07.007We developed a protocol that analyses both CFTR
function and protein in the same sample ex vivo. Freshly
obtained rectal suction biopsies mounted in mini-Ussing
chambers are characterized in their chloride secretory
responses towards secretagogues and inhibitors (Fig. 1A)
[4]. Immediately thereafter the mucosal biopsies are lysed,
immunoprecipitated with a cocktail of polyclonal anti-
hCFTR antibodies, and CFTR immunoreactive bands are
visualized on immunoblot with monoclonal antibodies
against hCFTR (Fig. 1B) [5].
The splice mutation 2789+5 G-A in the human CFTR
gene is known to be associated with mild CF [6–8]. The
initial analysis of affected members of a large inbred
pedigree showed that the G-to-A substitution at position+5
of the splice donor site in intron 14b leads to skipping of the
38-bp exon 14b and a frameshift mutant CFTR mRNA.
Homozygosity for 2789+5 G-A produced approximately
4% of normally spliced CFTR mRNA transcript [6].
2. Case report
We had the opportunity to study the consequences of the
2789+5 G-A mutation on CFTR protein. The 6-year olded by Elsevier B.V. All rights reserved.
Fig. 1. Intestinal current measurements (A) and CFTR immunoblot (B) of
rectal biopsies of a carrier of the 2789+5 G-A mutation. (A). Freshly
obtained rectal suction biopsies equilibrated in Meyler's buffer [4] were
exposed to the mucosal (M) and/or serosal (S) side to: 1. amiloride (10−4 M,
−5
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bronchitis during the last three years. Since CF was
suspected as a probable cause of his respiratory disease,
the boy was referred to the CF center to make a diagnosis. No
clinical symptoms of CF were observed in the exocrine
pancreatic sufficient boy. The screening for common intron
mutations and the complete sequencing of all CFTR exons
and exon/intron boundaries uncovered heterozygosity for
2789+5 G-A. Pilocarpine iontophoresis sweat tests on
several occasions yielded chloride concentrations in the
borderline range of 30 to 60 mM chloride. Intestinal current
measurements [4] of rectal suction biopsies demonstrated
normal chloride secretory responses (Fig. 1A) consistent
with the genetic diagnosis of a heterozygous carrier of a
CFTR mutation. The immunoblot [2,5] of the proband's
mucosal biopsies revealed three interpretable CFTR immu-
noreactive bands (Fig. 1B). Interestingly, CFTR band B that
under standard conditions was barely visible in samples
taken from 18 healthy individuals, was a prominent band in
the index case as strong as the band C of mature CFTR [9]
indicating that the sample contained substantial amounts of
the immature core-glycosylated CFTR isoform. The third
immunoreactive band was observed in the 100–115 kDa
range. Signal intensity was stronger in the index case than in
healthy non-CF controls (Fig. 1B). The band was interpreted
to represent a superposition of degradation forms of CFTR
designated P in Fig. 1B [10,11] (all tissue samples) and
mutant CFTR protein designated M in Fig. 1B (index caseonly). Skipping of exon 14B leads to a CFTR mRNA trans-
cript that encodes a truncated 892 amino acids large 102 kDa
CFTR protein that lacks the consensus N-glycosylation sites
at N894 and N900 [9]. CFTR forms of slightly lower
molecular weight result from limited proteolysis at predis-
posed sites in the R domain [10,11].
The authors have examined nine individuals with CF at
our clinic who are compound heterozygous for 2789+5 G-A
and another PI CF allele (seven F508del, one 2043delG, one
E92X [7]). All individuals were exocrine pancreatic
sufficient, had normal weight throughout their lifetime and
showed elevated chloride concentrations of 80–130 mM
chloride in sweat tests. The number of patients with normal
lung function declined from four by age 20 to two by age 30
and one by age 40, respectively. Three patients died from
pulmonary disease at the age of 27, 38, and 41 years, and two
patients received lung transplants at the age of 29 and
35 years. The alive non-transplanted patients were 2007 25,
34, 45, and 48 years old. Two F508del/2789+5 G-A
compound heterozygotes with mild pulmonary manifestation
treated at another CF clinic are the oldest living CF siblings in
Germany [12]. Nasal potential difference measurementsM), 2. indomethacin (10 M, M+S), to reduce basal chloride secretion by
inhibiting the endogenous prostaglandin formation; 3. carbachol (10−4 M,
S), to initiate the cholinergic Ca2+-linked chloride secretion; 4. forskolin
(10−5 M, M+S) together with 8-bromo-cAMP (10−3 M, M+S), to open
cAMP-dependent Cl−channels like CFTR; 5. 4,4′-diisothiocyanatostilbene-
2,2′-disulfonic acid (DIDS, 2.10−4 M,M), to inhibit DIDS-sensitive
Cl−transporters like the Ca2+-dependent Cl− channels and the ORCC;
6. histamine (5.10−4 M, S), to reactivate the Ca2+-dependent chloride
secretory pathway [4]. The evoked responses are in the normal range of
healthy non-CF controls [4]. It should be noted that both carbachol and
histamine elicited initially a brief negative response indicative for a net
excess of potassium over chloride secretion at the beginning [14]. This
response is atypical for non-CF probands, but is characteristic for most CF
patients with residual chloride secretion [4,14]. (B) T84 cells or rectal
biopsies were homogenized [5], lysed with 0.02% SDS for 30 min, followed
by 1% (v/v) Triton X-100 and 0.5% (w/v) sodium deoxycholate for 40 min,
and centrifuged (16,000 g, 4 °C, 20 min). After incubation with protein A-
sepharose (PAS) for 60 min, the supernatant was immunoprecipitated with
rabbit polyclonal antibodies R39, R40 (raised against hCFTR peptide 1465–
1480) and R453 (raised against CFTR peptides 1–14 and 1466–1480) [5] in
the presence of PAS. CFTR immunoreactive bands were detected on 5%
SDS-PAGE separated immunoblots with monoclonal antibodies 570 and
596 (raised against linear epitopes in the R domain and NBD2, respectively,
1:1000) [2] and anti-mouse-IgG-HRP from donkey (1:50,000) using ECL
Advance (Amersham Bioscience). Arrowheads indicate the positions of
fully glycosylated mature CFTR (C-band) [9] and core-glycosylated CFTR
(B-band) [9] in T84 cells and rectal biopsies sampled from the index case
and two normal non-CF controls (from left to right). The arrowhead M
points to the position of the predicted truncated isoform translated from
mutant CFTR mRNA transcript with a premature termination codon derived
from the 2789+5 G-A allele. The arrowhead P points to the expected
position of degradation forms that result from proteolysis of CFTR at
predisposed sites in the R domain [10,11] (see text). The gel was calibrated
with the Precision Plus Protein Standards (BIO-RAD).
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residual CFTR function in the upper airways. In summary,
consistent with clinical data from the French CF registry [8],
the 2789+5 G-A splice mutation is associated with normal
anthropometry, salt loss by sweat glands and progressive
pulmonary disease.
3. Discussion
The rather uniform genotype–phenotype associations in
2789+5 G-A compound heterozygous patients indicate that
truncated CFTR and/or small amounts of normal CFTR may
provide some tissue-specific rescue from manifestation of
clinical symptoms. The mutant protein contains a complete
N-terminal half and the R domain. The recombinant N-
terminal portion of CFTR (D836X) forms proper chloride
channels in vitro [13], albeit the cooperation between the two
non-equivalent NBDs in the binding and hydrolysis of
nucleotides cannot take place [9]. If this in vitro data reflects
the situation in vivo, the small portion of full-length protein
and the major portion of truncated TM1-NBD1-R CFTR
derived from the 2789+5 G-A allele may be sufficient for
proper function of some epithelial tissues such as the
intestine but not for that of others such as the sweat gland
where CFTR is involved in both secretion and re-absorption
of salt.
The ex vivo CFTR protein analysis showed an unexpect-
ed influence of the 2789+5 G-A splice site mutation on the
relative amounts of full length CFTR isoforms demonstrat-
ing that in contrast to common practise splice site mutations
should be studied at the mRNA and protein levels to properly
interpret the associations between genotype, pathophysiol-
ogy and clinical manifestations of CF.
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